Revolution Medicines, based on research from University of Illinois at Urbana-Champaign, Stanford University and UC Berkeley, has filed for a $100m initial public offering.

Sanofi is in line for an exit as Revolution Medicines files for a $100m initial public offering on the Nasdaq Global Market.

Bertelsmann achieved an exit as the cloud services provider raised $284m in an initial public offering that reportedly valued it at about $2bn.

The Bertelsmann, UCommune and Ant Financial-backed property manager raised nearly $130m depite downsizing its initial public offering.

The Tasly and Genexine-backed drug developer floated above the mid-point of its range, in an initial public offering that could end up topping $119m.

The Xiaomi-backed, China-headquartered podcast app developer priced its shares at the bottom of their range to raise $45.1m in a US offering.

Ping An's financial technology spinoff, which also counts SoftBank Vision Fund and SBI as shareholders, has sold an additional $35.2m in shares in the offering.

Minsheng Life-backed oncology drug developer Zelgen has priced an initial public offering set to value it at more than $1.1bn.

Opt, NTT Docomo, Lilfull, Japan Best Rescue System and Proto Corporation could exit the classified listings platform, which has received approval for a Tokyo IPO.

Target-backed sleep product provider Casper has set a $100m placeholder target for its initial public offering, having been valued at $1.1bn early last year.